-
Jan 16, 2025 | 00875-x&sz=64)
cell.com | Zhiming Li |Zhiguo Zhang
KeywordsDNA replicationstrand-specific sequencingepigenetic inheritanceparental histone transfernucleosome assemblyDNA damage repairgenome maintenanceIntroductionDNA replication is essential to all living organisms and entails a highly orchestrated process, ensuring the faithful transmission of genetic information from one generation to the next.
-
Jan 3, 2025 | 
mdpi.com | Zhiming Li
Article Menu /ajax/scifeed/subscribe Altmetric announcement Help format_quote Cite thumb_up ... Endorse Need Help? Find support for a specific problem in the support section of our website. Please let us know what you think of our products and services. Visit our dedicated information section to learn more about MDPI.
-
Dec 27, 2024 | 00943-7/abstract?rss=yes&sz=64)
academicradiology.org | Bo Wang |Xiaomeng Han |Zaixian Zhang |Hongzheng Song |Yaolin Song |RuiQing Liu | +2 more
Abbreviations LAGC (locally advanced gastric cancer) NAC (neoadjuvant chemotherapy) NCCN (The National Comprehensive Cancer Network) TRG (tumor regression grading) RECIST (The Response Evaluation Criteria in Solid Tumors) ypTNM (pathological stage) C-index (The concordance index) IBS (the integrated broker score) DCA (Decision curve analysis) Pre-Rad (the baseline radiomics signature) Post-Rad (the restaging radiomics signature) Delta-Rad (the delta radiomics signature) PrePost-Rad (the...
-
Dec 4, 2024 | 
nature.com | Weiming Yang |Zhiming Li
AbstractSoft-magnetic fibers (SMFs) play a crucial role in energy conversion, transmission, and storage within electronic devices. However, conventional SMFs have poor plasticity and are therefore difficult to withstand long-term tensile, torsional, and shear deformation. A high fraction of grain boundaries could improve plastic deformability of conventional SMFs, but deteriorates the coercivity. This severely limits their applications in flexible electronics and multifunctional components.
-
Oct 29, 2024 | 
arxiv.org | Yuguang Yao |Zhen Tan |Zhiming Li |Pan Wang
arXivLabs is a framework that allows collaborators to develop and share new arXiv features directly on our website. Both individuals and organizations that work with arXivLabs have embraced and accepted our values of openness, community, excellence, and user data privacy. arXiv is committed to these values and only works with partners that adhere to them. Have an idea for a project that will add value for arXiv's community? Learn more about arXivLabs.
-
Oct 5, 2024 | 
mdpi.com | Meili Zhao |Zhiming Li |Chengwei Liu |Shiqin Yuan
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
-
Oct 1, 2024 | 
jitc.bmj.com | Zhiming Li |Wenqi Jiang |Hui Zhou |Hong Cen
MethodsThis was a multicenter, double-blind, randomized phase 3 clinical trial, in which eligible patients were assigned randomly in a 2:1 ratio to either the Hi-CHOP group or the R-CHOP group to receive six cycles of either zuberitamab or rituximab plus conventional CHOP treatment. Patients ranged in age from 18 to 75 years, and a survival time of >6 months was anticipated.
-
Aug 20, 2024 | 
mdpi.com | Moyan Wang |Zhiming Li |Zhengyuan Liang
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
-
Jul 12, 2024 | 
mdpi.com | Guifang Zhang |Zhiming Li |Shu Zhang |Lu Bai
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
-
May 16, 2024 | 
nature.com | Wei Xu |Qingqing Cai |Zhiming Li
AbstractAnti-PD-1 antibodies are a favorable treatment for relapsed or refractory extranodal natural killer T cell lymphoma (RR-ENKTL), however, the complete response (CR) rate and the duration of response (DOR) need to be improved. This phase 1b/2 study investigated the safety and efficacy of sintilimab, a fully human anti-PD-1 antibody, plus chidamide, an oral subtype-selective histone deacetylase inhibitor in 38 patients with RR-ENKTL.
